About Mucosa-Associated Lymphoid Tissue (MALT) The mucosa-associated lymphoid tissue (MALT), also called mucosa-associated lymphatic tissue, is a diffuse system of small concentrations of lymphoid tissue found in various submucosal membrane sites of the body, such as the gastrointestinal tract, nasopharynx, thyroid, breast, lung, salivary glands, eye, and skin. MALT is populated by lymphocytes such as T cells and B cells, as well as plasma cells and macrophages, each of which is well situated to encounter antigens passing through the mucosal epithelium. In the case of intestinal MALT, M cells are also present, which sample antigen from the lumen and deliver it to the lymphoid tissue. MALT constitute about 50% of the lymphoid tissue in human body. Immune responses that occur at mucous membranes are studied by mucosal immunology. 1 kind of targeted therapies for the treatment of Mucosa-Associated Lymphoid Tissue can be made in Laos Ibrutinib Targeted therapy MALT lymphoma in the stomach doesn’t respond to antibiotics if the lymphoma is not linked with H. pylori infection or if the lymphoma comes […]
About Mantle Cell Lymphoma (MCL) Mantle cell lymphoma is a rare type of non-Hodgkin lymphoma that arises in B cells, a type of white blood cell. Most people with mantle cell lymphoma are diagnosed with aggressive, widespread disease. Unlike some other types of aggressive lymphomas, however, mantle cell lymphoma is rarely curable with current therapies. 5 kinds of targeted therapies for the treatment of Mantle Cell Lymphoma can be made in Laos Ibrutinib Zanubrutinib Acalabrutinib Orelabrutinib Lenalidomide Targeted therapy Two Bruton tyrosine kinase inhibitors (BTKi), one In November 2013, ibrutinib (trade name Imbruvica, Pharmacyclics LLC) and in October 2017, acalabrutinib (trade name Calquence, AstraZeneca Pharmaceuticals LP) were approved in the United States for treating MCL. Other targeted agents include the proteasome inhibitor bortezomib, mTOR inhibitors such as temsirolimus, and the P110δ inhibitor GS-1101. Bruton’s tyrosine kinase (BTK) inhibitors: A substance that blocks the action of enzymes called tyrosine kinases. Tyrosine kinases are a part of […]
About Non Small Cell Lung Carcinoma (NSCLC) Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small-cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small-cell carcinoma. When possible, they are primarily treated by surgical resection with curative intent, although chemotherapy has been used increasingly both preoperatively (neoadjuvant chemotherapy) and postoperatively (adjuvant chemotherapy). 2 kinds of targeted drugs for the treatment of About KRAS-mutated non-small cell lung cancer can be made in Laos Sotorasib Adagrasib Targeted therapy Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Targeted therapies usually cause less harm to normal cells than chemotherapy or radiation therapy do. Monoclonal antibodies, tyrosine kinase inhibitors, and mammalian target of rapamycin (mTOR) inhibitors are three types of targeted therapy being used to […]
About Non Small Cell Lung Carcinoma (NSCLC) Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small-cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small-cell carcinoma. When possible, they are primarily treated by surgical resection with curative intent, although chemotherapy has been used increasingly both preoperatively (neoadjuvant chemotherapy) and postoperatively (adjuvant chemotherapy). 4 kinds of targeted drugs for the treatment of About RET fusion-positive non small cell lung cancer can be made in Laos Selpercatinib Pralsetinib Cabozantinib Vandetanib Targeted therapy Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Targeted therapies usually cause less harm to normal cells than chemotherapy or radiation therapy do. Monoclonal antibodies, tyrosine kinase inhibitors, and mammalian target of rapamycin (mTOR) inhibitors are three types of targeted […]
The drugs produced by the Lao pharmaceutical industry are basically generic drugs. A generic drug is a drug that is identical in dosage form, safety, strength, route of administration, quality and performance characteristics to an existing approved brand-name drug.The following is not a list of medicines manufactured by the entire Lao pharmaceutical industry, but is a list of products we have obtained from manufacturers that are making or can help make them. The list is mainly to help customers understand what products are being produced by the pharmaceutical industry in Laos.
